Ranbaxy's US FDA case may hurt other Indian pharmas

Pharma major Ranbaxy is in trouble again with US FDA. Now the US FDA has issued two warnings to Ranbaxy for drugs made at two of its plants in India . As a results the US agency says it will refuse to approve any new products till Ranbaxy responds. This could have far reaching implications for the pharmaceutical industry in general.